At the Panacea Biotec office, conversations around DengiAll are cloaked with an air of eagerness. With the human trials enrollment ending with over 10,000 participants, the company is waiting for approval.
With govt's local clinical trials waiver for certain drugs and vaccines, Japanese firm Takeda may soon launch QDenga, which will be a boost for India’s fight against dengue.
Study raises need for vaccines to protect those who have not been infected. 619 children in 3 hospitals across India were part of study, published in Nature Medicine in February.
Takeda's QDENGA, designed to protect against all 4 dengue virus serotypes, has been recommended by Strategic Advisory Group of Experts on Immunization for use in endemic countries.
IAF is firming up plans to revamp airlift capabilities with medium transport aircraft that will be assembled in India & serve as its main workhorse. Embraer is leading contender as of now.
This is the game every nation is now learning to play. Some are finding new allies or seeing value among nations where they’d seen marginal interest. The starkest example is India & Europe.
COMMENTS